XARELTO Market, By Indications (Nonvalvular Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Recurrent DVT or PE, Pos Knee or Hip Replacement Surgery, Venous Thromboembolism (VTE) in Acutely Ill Patients, Pediatric VTE, Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Post-Fontan Procedure in Congenital Heart Disease (CHD)), By Dosage Form (Tablets and Oral Suspension), By Strength (2.5 mg, 10 mg, 15 mg, 20 mg, and 1 mg/mL), By Age Group (Pediatric, Adult, and Geriatric), By Gender (Male and Female), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others (Academic and Research Institutes, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Select a License Type that Suits your Business Needs
US$ 2,000
Two thousand dollars
Single User License
( Full Report )
US$ 4,500
US$ 3,000
Three thousand dollars
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 5,000
Five thousand dollars
Corporate User License
( Full Report )
US$ 10,000
US$ 6000
Six thousand dollars
Client Testimonials
Client Testimonials
Our Clients
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

860519526
9001:2015
27001:2022